Medicine
Voquezna 13.36 mg tablet
Voquezna 13.36 mg tablet is a prescription medicine containing Vonoprazan for oral use, marketed by Phathom Pharmaceuticals, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store between 20°C and 25°C (68°F and 77°F), excursions permitted between 15°C…
Key facts
- Active ingredient (INN)
- Vonoprazan
- Brand
- Voquezna
- Strength
- 13.36 mg
- Dosage form
- Tablet
- Route
- Oral
- Packs
- 30 tablets
- Marketing authorisation holder
- Phathom Pharmaceuticals
- Manufacturer
- Phathom Pharmaceuticals
- Origin register
- US FDA, United States
- Storage
- Store between 20°C and 25°C (68°F and 77°F), excursions permitted between 15°C and 30°C (59°F and 86°F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 10 November 2023
- Identifiers
- RxCUI 2604800, 2669507, 2669513 +1DailyMed set ID 0cc52ac5-77ec-4d66-a770-762a1a960914NDC 81520-100Application NDA215151
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 30 tablet in 1 bottle, plastic | 81520-100-30 | Phathom Pharmaceuticals | 10 November 2023 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 1 November 2023 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Vonoprazan
Clinical summary
Vonoprazan is a prescription medicine indicated for healing of all grades of erosive esophagitis and relief of heartburn associated with erosive esophagitis in adults. It is available as tablets for oral use. MedsAcross supplies Vonoprazan for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about VonoprazanFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- VOQUEZNA prescribing information (Phathom Pharmaceuticals) · U.S. National Library of Medicine, DailyMed
Need Voquezna 13.36 mg tablet for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.